Is QURE or IMMX more profitable?

Immix Biopharma has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Immix Biopharma's return on equity of -73.24% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,154.42% -145.81% -27.15% Immix Biopharma N/A -73.24% -59.20%

Does the media refer more to QURE or IMMX?

In the previous week, uniQure had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for uniQure and 4 mentions for Immix Biopharma. uniQure's average media sentiment score of 0.79 beat Immix Biopharma's score of 0.79 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NRIX or IMMX?

In the previous week, Nurix Therapeutics had 18 more articles in the media than Immix Biopharma. MarketBeat recorded 22 mentions for Nurix Therapeutics and 4 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.79 beat Nurix Therapeutics' score of 0.30 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 3 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Immix Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, MLYS or IMMX?

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mineralys Therapeutics N/A N/A -$154.65M -$2.05 N/A Immix Biopharma N/A N/A -$29.44M -$0.92 N/A

Is MLYS or IMMX more profitable?

Mineralys Therapeutics' return on equity of -27.92% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Mineralys Therapeutics N/A -27.92% -26.98% Immix Biopharma N/A -73.24% -59.20%

Does the media favor MLYS or IMMX?

In the previous week, Mineralys Therapeutics had 5 more articles in the media than Immix Biopharma. MarketBeat recorded 9 mentions for Mineralys Therapeutics and 4 mentions for Immix Biopharma. Mineralys Therapeutics' average media sentiment score of 1.11 beat Immix Biopharma's score of 0.79 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NTLA or IMMX?

In the previous week, Intellia Therapeutics had 9 more articles in the media than Immix Biopharma. MarketBeat recorded 13 mentions for Intellia Therapeutics and 4 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.79 beat Intellia Therapeutics' score of 0.44 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immix Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, VCEL or IMMX?

Vericel has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 8.78 $16.52M $0.42 113.07 Immix Biopharma N/A N/A -$29.44M -$0.92 N/A

Does the media refer more to VCEL or IMMX?

In the previous week, Vericel had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Vericel and 4 mentions for Immix Biopharma. Vericel's average media sentiment score of 1.02 beat Immix Biopharma's score of 0.79 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immix Biopharma (IMMX) Competitors

$10.52 -0.59 (-5.31%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$10.78 +0.26 (+2.42%)

As of 07/13/2026 06:42 PM Eastern

Compare

IMMX vs. QURE, NRIX, MLYS, NTLA, and VCEL

Should you buy Immix Biopharma stock or one of its competitors? MarketBeat compares Immix Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immix Biopharma include uniQure (QURE), Nurix Therapeutics (NRIX), Mineralys Therapeutics (MLYS), Intellia Therapeutics (NTLA), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry.

How does Immix Biopharma compare to uniQure?

uniQure (NASDAQ:QURE) and Immix Biopharma (NASDAQ:IMMX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

uniQure has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

uniQure presently has a consensus price target of $64.17, suggesting a potential upside of 56.12%. Immix Biopharma has a consensus price target of $20.67, suggesting a potential upside of 96.45%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Immix Biopharma is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, uniQure had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for uniQure and 4 mentions for Immix Biopharma. uniQure's average media sentiment score of 0.79 beat Immix Biopharma's score of 0.79 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immix Biopharma has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	161.00	-$198.97M	-$3.48	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

78.8% of uniQure shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Immix Biopharma has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Immix Biopharma's return on equity of -73.24% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Immix Biopharma	N/A	-73.24%	-59.20%

Summary

Immix Biopharma beats uniQure on 8 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Immix Biopharma (NASDAQ:IMMX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Nurix Therapeutics had 18 more articles in the media than Immix Biopharma. MarketBeat recorded 22 mentions for Nurix Therapeutics and 4 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.79 beat Nurix Therapeutics' score of 0.30 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	3 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.3% of Immix Biopharma shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Immix Biopharma has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Immix Biopharma's return on equity of -73.24% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Immix Biopharma	N/A	-73.24%	-59.20%

Nurix Therapeutics presently has a consensus target price of $34.08, suggesting a potential upside of 50.05%. Immix Biopharma has a consensus target price of $20.67, suggesting a potential upside of 96.45%. Given Immix Biopharma's higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Nurix Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Immix Biopharma has lower revenue, but higher earnings than Nurix Therapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	28.06	-$264.46M	-$3.45	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

Summary

Immix Biopharma beats Nurix Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Immix Biopharma compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Immix Biopharma (NASDAQ:IMMX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Mineralys Therapeutics' return on equity of -27.92% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Immix Biopharma	N/A	-73.24%	-59.20%

Mineralys Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Mineralys Therapeutics currently has a consensus price target of $49.33, suggesting a potential upside of 78.81%. Immix Biopharma has a consensus price target of $20.67, suggesting a potential upside of 96.45%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Immix Biopharma is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

In the previous week, Mineralys Therapeutics had 5 more articles in the media than Immix Biopharma. MarketBeat recorded 9 mentions for Mineralys Therapeutics and 4 mentions for Immix Biopharma. Mineralys Therapeutics' average media sentiment score of 1.11 beat Immix Biopharma's score of 0.79 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 18.9% of Mineralys Therapeutics shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Immix Biopharma beats Mineralys Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Immix Biopharma compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Intellia Therapeutics had 9 more articles in the media than Immix Biopharma. MarketBeat recorded 13 mentions for Intellia Therapeutics and 4 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.79 beat Intellia Therapeutics' score of 0.44 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Immix Biopharma has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Immix Biopharma	N/A	-73.24%	-59.20%

Immix Biopharma has lower revenue, but higher earnings than Intellia Therapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	26.88	-$412.69M	-$3.54	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

Intellia Therapeutics currently has a consensus target price of $20.67, indicating a potential upside of 58.79%. Immix Biopharma has a consensus target price of $20.67, indicating a potential upside of 96.45%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Immix Biopharma is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Intellia Therapeutics beats Immix Biopharma on 9 of the 16 factors compared between the two stocks.

How does Immix Biopharma compare to Vericel?

Vericel (NASDAQ:VCEL) and Immix Biopharma (NASDAQ:IMMX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Vericel has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Vericel presently has a consensus target price of $52.50, indicating a potential upside of 10.55%. Immix Biopharma has a consensus target price of $20.67, indicating a potential upside of 96.45%. Given Immix Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Immix Biopharma is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Vericel has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.78	$16.52M	$0.42	113.07
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A

In the previous week, Vericel had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Vericel and 4 mentions for Immix Biopharma. Vericel's average media sentiment score of 1.02 beat Immix Biopharma's score of 0.79 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vericel has a net margin of 7.35% compared to Immix Biopharma's net margin of 0.00%. Vericel's return on equity of 6.41% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Immix Biopharma	N/A	-73.24%	-59.20%

11.3% of Immix Biopharma shares are owned by institutional investors. 7.6% of Vericel shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Vericel beats Immix Biopharma on 10 of the 15 factors compared between the two stocks.

Get Immix Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMX vs. The Competition

Export

Metric	Immix Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$604.51M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-11.43	20.85	27.15	24.26
Price / Sales	N/A	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	5.94	8.49	10.75	6.29
Net Income	-$29.44M	$23.83M	$3.58B	$330.66M
7 Day Performance	-12.48%	-3.56%	-2.07%	-1.32%
1 Month Performance	24.50%	6.31%	3.31%	-0.64%
1 Year Performance	264.01%	48.30%	26.35%	19.08%

Immix Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMX Immix Biopharma	3.4276 of 5 stars	$10.52 -5.3%	$20.67 +96.5%	+297.0%	$604.51M	N/A	N/A	9	News Coverage Short Interest Increase
QURE uniQure	3.7521 of 5 stars	$43.49 +5.0%	$64.17 +47.5%	+185.4%	$2.61B	$16.10M	N/A	500
NRIX Nurix Therapeutics	3.5333 of 5 stars	$24.31 -0.4%	$32.20 +32.5%	+82.6%	$2.52B	$83.98M	N/A	300	Earnings Report Analyst Forecast Gap Down
MLYS Mineralys Therapeutics	3.1675 of 5 stars	$30.40 -0.2%	$49.33 +62.3%	+90.4%	$2.51B	N/A	N/A	28	Positive News
NTLA Intellia Therapeutics	3.2373 of 5 stars	$16.84 -3.4%	$20.46 +21.5%	+12.9%	$2.44B	$67.67M	N/A	600	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immix Biopharma (IMMX) Competitors

IMMX vs. QURE, NRIX, MLYS, NTLA, and VCEL

How does Immix Biopharma compare to uniQure?

Summary

How does Immix Biopharma compare to Nurix Therapeutics?

Summary

How does Immix Biopharma compare to Mineralys Therapeutics?

Summary

How does Immix Biopharma compare to Intellia Therapeutics?

Summary

How does Immix Biopharma compare to Vericel?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immix Biopharma (IMMX) Competitors

IMMX vs. QURE, NRIX, MLYS, NTLA, and VCEL

How does Immix Biopharma compare to uniQure?

Which has more volatility & risk, QURE or IMMX?

Do analysts prefer QURE or IMMX?

Does the media refer more to QURE or IMMX?

Which has stronger earnings and valuation, QURE or IMMX?

Do institutionals & insiders hold more shares of QURE or IMMX?

Is QURE or IMMX more profitable?

Summary

How does Immix Biopharma compare to Nurix Therapeutics?

Does the media refer more to NRIX or IMMX?

Do insiders & institutionals hold more shares of NRIX or IMMX?

Is NRIX or IMMX more profitable?

Do analysts recommend NRIX or IMMX?

Which has more volatility and risk, NRIX or IMMX?

Which has preferable valuation and earnings, NRIX or IMMX?

Summary

How does Immix Biopharma compare to Mineralys Therapeutics?

Is MLYS or IMMX more profitable?

Which has more risk and volatility, MLYS or IMMX?

Do analysts recommend MLYS or IMMX?

Which has preferable valuation & earnings, MLYS or IMMX?

Does the media favor MLYS or IMMX?

Do institutionals & insiders have more ownership in MLYS or IMMX?

Summary

How does Immix Biopharma compare to Intellia Therapeutics?

Do institutionals and insiders believe in NTLA or IMMX?

Does the media refer more to NTLA or IMMX?

Which has more risk and volatility, NTLA or IMMX?

Is NTLA or IMMX more profitable?

Which has higher valuation and earnings, NTLA or IMMX?

Do analysts rate NTLA or IMMX?

Summary

How does Immix Biopharma compare to Vericel?

Which has more volatility and risk, VCEL or IMMX?

Do analysts prefer VCEL or IMMX?

Which has preferable valuation and earnings, VCEL or IMMX?

Does the media refer more to VCEL or IMMX?

Is VCEL or IMMX more profitable?

Do institutionals and insiders believe in VCEL or IMMX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX vs. The Competition

Immix Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools